

VOLITIONRX LTD  
Form 10-Q  
May 10, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2018**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 001-36833**

**VOLITIONRX LIMITED**

(Exact name of registrant as specified in its charter)

**Delaware** **91-1949078**  
(State or other jurisdiction of incorporation (I.R.S. Employer Identification No.)  
or organization)

Edgar Filing: VOLITIONRX LTD - Form 10-Q

**1 Scotts Road**

**#24-05 Shaw Centre**

**Singapore 228208**

(Address of principal executive offices)

**+1 (646) 650-1351**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]

Accelerated filer [ ]

Non-accelerated filer [ ] (Do not check if a smaller reporting company)

Smaller reporting company [X]

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).[ ]  
Yes [X] No

Edgar Filing: VOLITIONRX LTD - Form 10-Q

As of May 8, 2018, there were 30,030,793 shares of the registrant's \$0.001 par value common stock issued and outstanding.

**VOLITIONRX LIMITED**

**QUARTERLY REPORT ON FORM 10-Q**

**FOR THE THREE MONTHS ENDED MARCH 31, 2018**

**TABLE OF CONTENTS**

		<b>PAGE</b>
<b>PART I</b>	<b>FINANCIAL INFORMATION</b>	
ITEM 1.	FINANCIAL STATEMENTS	3
ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22
ITEM 4.	CONTROLS AND PROCEDURES	22
<b>PART II</b>	<b>OTHER INFORMATION</b>	
ITEM 1	LEGAL PROCEEDINGS	23
ITEM 1A.	RISK FACTORS	23
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	24
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	24
ITEM 4.	MINE SAFETY DISCLOSURES	24
ITEM 5.	OTHER INFORMATION	24
ITEM 6.	EXHIBITS	24
SIGNATURES		25

**Use of Terms**

Except as otherwise indicated by the context, references in this report to “Company,” “VolitionRx,” “Volition,” “we,” “us” and “our” are references to VolitionRx Limited and its wholly-owned subsidiaries, Singapore Volition Pte. Limited, Belgian Volition SPRL, Hypergenomics Pte. Limited, Volition America, Inc. and Volition Diagnostics UK Limited. Additionally, unless otherwise specified, all references to “United States Dollars” or “\$” refer to the legal currency of the United States of America.

Nucleosomics®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx. All other trademarks, service marks and trade names referred to in this report are the property of their respective owners.

**PART I - FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

	<b>PAGE</b>
Condensed Consolidated Balance Sheets (Unaudited)	4
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	5
Condensed Consolidated Statements of Cash Flows (Unaudited)	6
Notes to the Condensed Consolidated Financial Statements (Unaudited)	7

**VOLITIONRX LIMITED**

## Condensed Consolidated Balance Sheets

(Expressed in United States Dollars, except share numbers)

	<b>March 31, 2018</b>	<b>December 31, 2017</b>
	<b>\$</b>	<b>\$</b>
	(UNAUDITED)	
<b>ASSETS</b>		
Cash and cash equivalents	14,260,282	10,116,263
Prepaid expenses	440,984	248,661
Other current assets	203,929	202,295
<b>Total Current Assets</b>	<b>14,905,195</b>	<b>10,567,219</b>
Property and equipment, net	3,510,426	3,480,782
Intangible assets, net	566,128	576,397
<b>Total Assets</b>	<b>18,981,749</b>	<b>14,624,398</b>
<b>LIABILITIES</b>		
Accounts payable	445,065	351,735
Accrued liabilities	1,485,941	1,278,428
Management and directors' fees payable	20,613	35,397
Current portion of long-term debt	474,712	443,908
Current portion of capital lease liabilities	144,015	139,084
Current portion of grant repayable	43,143	41,930
<b>Total Current Liabilities</b>	<b>2,613,489</b>	<b>2,290,482</b>
Long-term debt, net of current portion	1,296,791	1,312,785
Capital lease liabilities, net of current portion	863,620	874,684
Grant repayable, net of current portion	194,030	188,579

Total Liabilities	4,967,930	4,666,530
-------------------	-----------	-----------

**STOCKHOLDERS' EQUITY**

## Common Stock

Authorized: 100,000,000 shares of common stock, at \$0.001 par value

Issued and outstanding: 30,030,793 shares and 26,519,394 shares, respectively	30,031	26,519
---	--------	--------

Additional paid-in capital	74,464,783	65,774,870
----------------------------	------------	------------

Accumulated other comprehensive loss	(114,396)	(129,343)
--------------------------------------	-----------	-----------

Accumulated deficit	(60,366,599)	(55,714,178)
---------------------	--------------	--------------

Total Stockholders' Equity	14,013,819	9,957,868
----------------------------	------------	-----------

Total Liabilities and Stockholders' Equity	18,981,749	14,624,398
--	------------	------------

(The accompanying notes are an integral part of these condensed consolidated financial statements)



**VOLITIONRX LIMITED**

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(Expressed in United States Dollars, except share numbers)

	<b>Three-Months Ended March 31,</b>	
	<b>2018</b>	<b>2017</b>
	<b>\$</b>	<b>\$</b>
<b>Revenue</b>	–	–
<b>Operating Expenses</b>		
Research and development	2,423,202	1,668,386
General and administrative	1,842,093	1,400,684
Sales and marketing	364,144	269,408
<b>Total Operating Expenses</b>	4,629,439	3,338,478
<b>Operating Loss</b>	(4,629,439)	(3,338,478)
<b>Other Expenses</b>		
Interest expense	22,982	12,205
<b>Total Other Expenses</b>	(22,982)	(12,205)
<b>Provision for Income Taxes</b>	–	–
<b>Net Loss</b>	(4,652,421)	(3,350,683)
<b>Other Comprehensive Loss</b>		
Foreign currency translation adjustments	14,947	31,505
<b>Net Comprehensive Loss</b>	(4,637,474)	(3,319,178)
<b>Loss per Share – Basic and Diluted</b>	(0.17)	(0.13)
<b>Weighted Average Shares Outstanding – Basic and Diluted</b>	27,265,249	26,128,934

(The accompanying notes are an integral part of these condensed consolidated financial statements)

**VOLITIONRX LIMITED**

## Condensed Consolidated Statements of Cash Flows (Unaudited)

(Expressed in United States Dollars)

	<b>Three-Months Ended</b>	
	<b>March 31,</b>	
	<b>2018</b>	<b>2017</b>
	<b>\$</b>	<b>\$</b>
<b>Operating Activities:</b>		
Net loss	(4,652,421)	(3,350,683)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	156,362	93,277
Loss on disposal of property and equipment	-	1,929
Stock-based compensation	895,226	584,261
Warrants issued for services	2,199	9,945
Changes in operating assets and liabilities:		
Prepaid expenses	(192,323)	(178,011)
Other current assets	(155,521)	3,151
Accounts payable and accrued liabilities	439,943	166,243
Net Cash Used in Operating Activities	(3,506,535)	(2,669,888)
<b>Investing Activities:</b>		
Purchases of property and equipment	(60,658)	(874,891)
Net Cash Used in Investing Activities	(60,658)	(874,891)
<b>Financing Activities:</b>		
Net proceeds from issuance of common shares	7,796,000	43,300
Proceeds from debt payable	-	287,648
Payments on debt payable	(35,926)	-
Payments on capital lease obligations	(35,243)	(29,858)
Net Cash Provided by Financing Activities	7,724,831	301,090

Edgar Filing: VOLITIONRX LTD - Form 10-Q

Effect of foreign exchange on cash	(13,619)	37,919
Net change in cash and cash equivalents	4,144,019	(3,205,770)
Cash and cash equivalents – Beginning of Period	10,116,263	21,678,734
Cash and cash equivalents – End of Period	14,260,282	18,472,964
Supplemental Disclosures of Cash Flow Information:		
Interest paid	22,982	12,205
Income tax paid	-	-
Non-Cash Investing and Financing Activities:		
Common stock issued on cashless exercises of stock options	12	-
Capital lease obligation for equipment purchases	-	994,285

(The accompanying notes are an integral part of these condensed consolidated financial statements)

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 1 - Condensed Financial Statements**

The accompanying financial statements have been prepared by VolitionRx without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2018, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") have been condensed or omitted. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K, for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on March 1, 2018. The results of operations for the three month periods ended March 31, 2018 and 2017 are not necessarily indicative of the operating results for the full years.

**Note 2 - Going Concern**

The Company's financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of \$60,366,599, has negative cash flows from operations, and currently has no revenues, which creates substantial doubt about its ability to continue as a going concern for a period of one year from the date of issuance of these financial statements.

The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by: (a) securing additional grant funds; (b) obtaining additional equity or debt financing; (c) granting licenses to third parties in exchange for specified up-front and/or back end payments; and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.

The ability of the Company to continue as a going concern is dependent upon its accomplishment of the plans described in the preceding paragraph and eventually to attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

### **Note 3 - Summary of Significant Accounting Policies**

#### Basis of Presentation

The financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in United States Dollars. The Company's fiscal year end is December 31.

#### Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances.

The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 3 - Summary of Significant Accounting Policies (continued)**

Principles of Consolidation

The accompanying condensed consolidated financial statements for the period ended March 31, 2018 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte. Limited, Belgian Volition SPRL (“Belgian Volition”), Hypergenomics Pte. Limited, Volition America, Inc., and Volition Diagnostics UK Limited. All significant intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Loss Per Share

The Company computes loss per share in accordance with Accounting Standards Codification (“ASC”) 260, “Earnings Per Share,” which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of March 31, 2018, 1,962,547 dilutive warrants and options were excluded from the diluted EPS calculation as their effect is anti-dilutive. As of March 31, 2017, 1,386,887 dilutive warrants and options were excluded from the diluted EPS calculation as their effect is anti-dilutive.

Reclassification

Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation.

Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's consolidated financial statements.

---

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 4 - Property and Equipment**

The Company's property and equipment consist of the following amounts as of March 31, 2018 and December 31, 2017:

		Cost	Accumulated Depreciation	March 31, 2018 Net Carrying Value
	Useful Life	\$	\$	\$
Computer hardware and software	3 years	266,155	115,265	150,890
Laboratory equipment	5 years	1,659,015	751,751	907,264
Office furniture and equipment	5 years	199,995	48,689	151,306
Buildings	30 years	1,616,415	58,362	1,558,053
Building improvements	5-15 years	692,614	48,315	644,299
Land	Not amortized	98,614	-	98,614
		4,532,808	1,022,382	3,510,426

  

		Cost	Accumulated Depreciation	December 31, 2017 Net Carrying Value
	Useful Life	\$	\$	\$
Computer hardware and software	3 years	239,133	93,422	145,711
Laboratory equipment	5 years	1,575,354	653,636	921,718
Office furniture and equipment	5 years	207,208	54,479	152,729
Buildings	30 years	1,571,004	43,632	1,527,372
Building improvements	5-15 years	673,157	35,748	637,409
Land	Not amortized	95,843	-	95,843



4,361,699      880,917      3,480,782

During the three-month periods ended March 31, 2018 and March 31, 2017, the Company recognized \$137,705 and \$72,357, respectively, in depreciation expense.

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 5 - Intangible Assets**

The Company's intangible assets consist of intellectual property and patents, mainly acquired in the acquisition of Belgian Volition (formerly ValiBio SA). The patents and intellectual property are being amortized over the assets' estimated useful lives, which range from 8 to 20 years.

	March 31, 2018		
	Cost	Accumulated Amortization	Net Carrying Value
	\$	\$	\$
Patents	1,243,616	677,488	566,128
	December 31, 2017		
	Cost	Accumulated Amortization	Net Carrying Value
	\$	\$	\$
Patents	1,213,314	636,917	576,397

During the three-month periods ended March 31, 2018 and March 31, 2017, the Company recognized \$23,682 and \$20,920, respectively, in amortization expense.

The Company amortizes the long-lived assets on a straight-line basis with terms of 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:

2018- remaining	\$ 71,259
2019	\$ 94,941
2020	\$ 94,941
2021	\$ 94,941
2022	\$ 94,941
Thereafter	\$ 115,105
<b>Total</b>	<b>\$ 566,128</b>

The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2017. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2017.

#### **Note 6 - Related Party Transactions**

The Company has agreements with related parties for consultancy services, stock options and warrants.

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 7 - Common Stock**

As of March 31, 2018, the Company was authorized to issue 100 million shares of common stock par value \$0.001 per share, of which 30,030,793 and 26,519,394 shares were issued outstanding as of March 31, 2018 and December 31, 2017, respectively.

On March 13, 2018, the Company issued 3.5 million shares of common stock in a registered public offering at a price of \$2.40 per share, for aggregate gross proceeds of \$8.4 million. In connection with the transaction, \$0.6 million was incurred for legal and underwriting fees resulting in net proceeds of \$7.8 million. Pursuant to this offering, the underwriters had the option to purchase up to an additional 525,000 shares of common stock for 30 days following the pricing of the initial closing, which option was not exercised.

During the period ended March 31, 2018, 26,400 warrants were exercised to purchase shares of common stock at a price of \$2.00 per share in a cashless exercise that resulted in the issuance of 11,399 shares of common stock.

**Note 8 – Warrants and Options**

**a) Warrants**

The following table summarizes the changes in warrants outstanding of the Company during the three-month period ended March 31, 2018:

<b>Number of Warrants</b>	<b>Weighted</b>
---------------------------	-----------------

		<b>Average</b>
		<b>Exercise Price</b>
		(\$)
Outstanding at December 31, 2017	1,731,680	2.36
Granted	-	-
Exercised	(26,400)	2.00
Expired	-	-
Outstanding at March 31, 2018	1,705,280	2.37
Exercisable at March 31, 2018	1,580,280	2.36

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 8 – Warrants and Options (continued)**

Below is a table summarizing the warrants issued and outstanding as of March 31, 2018, which have a weighted average exercise price of \$2.37 per share and an aggregate weighted average remaining contractual life of 1.20 years.

			Weighted Average Remaining Contractual	Proceeds to Company if Exercised (\$)
Number Outstanding	Number Exercisable	Exercise Price (\$)	Life (Years)	
3,350	3,350	2.00	0.00	6,700
948,475	948,475	2.20	0.51	2,086,645
520,455	520,455	2.40	0.20	1,249,092
150,000	25,000	2.47	0.41	370,500
24,000	24,000	3.00	0.01	72,000
19,000	19,000	3.75	0.01	71,250
40,000	40,000	4.53	0.06	181,200
<b>1,705,280</b>	<b>1,580,280</b>		<b>1.20</b>	<b>4,037,387</b>

Warrant expense of \$2,199 and \$9,945 was recorded in the three-months ended March 31, 2018 and March 31, 2017, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is approximately \$23,391 and is expected to be recognized over a period of 2.8 years. As of March 31, 2018, the total intrinsic value of warrants was \$191,034.

**b) Options**

The following table summarizes the changes in options outstanding of the Company during the three-month period ended March 31, 2018:

	<b>Number of</b>	<b>Weighted</b>
	<b>Options</b>	<b>Average</b>
		<b>Exercise</b>
		<b>Price (\$)</b>
Outstanding at December 31, 2017	2,939,134	4.09
Granted	780,000	4.00
Exercised	-	-
Expired/Cancelled	(15,000)	5.44
Outstanding at March 31, 2018	3,704,134	4.06
Exercisable at March 31, 2018	2,814,134	4.04

Effective January 23, 2018, the Company granted stock options to purchase 780,000 shares of common stock. These options vest on January 23, 2019 and expire 5 years after the vesting date, with an exercise price of \$4.00 per share. The Company has calculated the estimated fair market value of these options at \$1,930,265, using the Black-Scholes model and the following assumptions: term 6 years, stock price \$3.75, exercise price \$4.00, 75.4% volatility, 2.55% risk free rate, and no forfeiture rate.

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 8 – Warrants and Options (continued)**

Below is a table summarizing the options issued and outstanding as of March 31, 2018, all of which were issued pursuant to the 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (the “2015 Plan”) (for option issuances commencing in 2016) and which have a weighted average exercise price of \$4.06 per share and a weighted average remaining contractual life of 3.74 years. As of March 31, 2018, an aggregate of 59,000 shares of common stock remained available for future issuance under the 2015 Plan.

			Weighted Average Remaining Contractual	Proceeds to Company if Exercised (\$)
Number Outstanding	Number Exercisable	Exercise Price (\$)	Life (Years)	
17,766	17,766	2.35	0.01	41,750
322,500	322,500	2.50	0.08	806,250
326,667	326,667	3.00	0.16	980,001
17,767	17,767	3.35	0.01	59,519
20,000	20,000	3.80	0.01	76,000
1,895,333	1,115,333	4.00	2.25	7,581,332
17,767	17,767	4.35	0.02	77,286
50,000	50,000	4.80	0.06	240,000
1,031,334	921,334	5.00	1.14	5,156,670
5,000	5,000	6.31	0.00	31,550
<b>3,704,134</b>	<b>2,814,134</b>		<b>3.74</b>	<b>15,050,358</b>

Stock option expense of \$895,226 and \$584,261 was recorded in the three-months ended March 31, 2018 and March 31, 2017, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is approximately \$1,588,446 and is expected to be recognized over a period of 0.8 years. As of March 31, 2018, the total intrinsic value of stock options was \$888.





**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 9 – Commitments and Contingencies**

**a) Capital Lease Obligations**

In 2015, the Company entered into an equipment capital lease to purchase three Tecan machines (automated liquid handling robots) for €550,454 Euros. As of March 31, 2018, the balance payable was \$220,707.

In 2016, the Company entered into a real estate capital lease with ING Asset Finance Belgium S.A. (“ING”) to purchase a property located in Belgium for €1.12 million Euros. As of March 31, 2018, the balance payable was \$786,928.

The following is a schedule showing the future minimum lease payments under capital leases by years and the present value of the minimum payments as of March 31, 2018.

2018- remaining	\$ 125,862
2019	\$ 167,814
2020	\$ 115,383
2021	\$ 66,302
2022	\$ 66,302
Greater than 5 years	\$ 621,552
Total minimum lease payments	\$ 1,163,215
Less: Amount representing interest	\$ (155,580)
<b>Present value of minimum lease payments</b>	<b>\$ 1,007,635</b>

**b) Operating Lease Obligations**

The Company also leases premises and facilities under operating leases with terms ranging from 12 months to 60 months. As of March 31, 2018, the annual non-cancelable operating lease payments on these leases are as follows:

2018- remaining	\$ 164,704
2019	\$ 66,241
2020	\$ 52,514
2021	\$ 14,404
<b>Total Operating Lease Obligations</b>	<b>\$ 297,863</b>

**c) Grants Repayable**

In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1.05 million Euros. Per the terms of the agreement, €314,406 Euros of the grant is to be repaid. As of March 31, 2018, the balance repayable was \$237,173 and the annual payments remaining were as follows:

2018- remaining	\$ 43,143
2019	\$ 43,143
2020	\$ 43,143
2021	\$ 39,946
2022	\$ 36,980
Greater than 5 years	\$ 30,818
<b>Total Grants Repayable</b>	<b>\$ 237,173</b>

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 9 – Commitments and Contingencies (continued)**

**d) Long-Term Debt**

In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 Euros with a fixed interest rate of 4.85%. As of March 31, 2018, the principal balance payable was \$494,267.

In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 Euros with a fixed interest rate of 2.62%. As of March 31, 2018, the principal balance payable was \$310,307.

In 2017, the Company entered into a 4-year loan agreement with Namur Invest for €350,000 Euros with a fixed interest rate of 4.00%. As of March 31, 2018, the principal balance payable was \$412,228.

In 2017, the Company entered into an 11-month loan agreement with ING for €200,000 Euros with a rolling interest rate of the Euribor rate + 2.00%. As of March 31, 2018, the principal balance payable was \$246,534.

In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million Euros with a fixed interest rate of 4.50%. As of March 31, 2018, €250,000 Euros has been drawn down under this agreement and the principal balance payable was \$308,167.

As of March 31, 2018, the total balance for long-term debt payable was \$1,771,503 and the annual payments remaining were as follows:

2018- remaining	\$ 461,570
2019	\$ 332,667
2020	\$ 552,240

Edgar Filing: VOLITIONRX LTD - Form 10-Q

2021	\$ 190,901
2022	\$ 124,750
Greater than 5 years	\$ 343,132
Total	\$ 2,005,260
Less: Amount representing interest	\$ (233,757)

**Total Long-Term Debt** **\$ 1,771,503**

---

**VOLITIONRX LIMITED**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(\$ expressed in United States Dollars)

**Note 9 – Commitments and Contingencies (continued)**

**e) Collaborative Agreement Obligations**

In 2015, the Company entered into a research sponsorship agreement with DKFZ, in Germany for a 3-year period for €338,984 Euros. As of March 31, 2018, \$92,450 is still to be paid by the Company under this agreement.

In 2016, the Company entered into a research co-operation agreement with DKFZ, in Germany for a 5-year period for €400,000 Euros. As of March 31, 2018, \$246,534 is still to be paid by the Company under this agreement.

In 2016, the Company entered into a collaborative research agreement with Munich University, in Germany for a 3-year period for €360,000 Euros. As of March 31, 2018, \$234,207 is still to be paid by the Company under this agreement.

In 2016, the Company entered into a phase one clinical research agreement with Hvidovre Hospital, University of Copenhagen in Denmark for a 2-year period for DKK 15 million Danish Kroner. As of March 31, 2018, \$708,639 is still to be paid by the Company under this agreement.

In 2017, the Company entered into a research collaboration agreement with National University of Singapore for a 2-year period for \$48,000. As of March 31, 2018, \$9,600 is still to be paid by the Company under this agreement.

In 2017, the Company entered into a clinical study research agreement with the Regents of the University of Michigan (the “University of Michigan”) for a 3-year period for up to \$3 million. As of March 31, 2018, up to \$2.5 million is still to be paid by the Company under this agreement.

As of March 31, 2018, the total amount to be paid for future research and collaboration commitments was \$3,791,430 and the annual payments remaining were as follows:

2018- remaining	\$ 2,228,334
2019	\$ 1,063,096
2020	\$ 500,000
<b>Total Collaborative Agreement Obligations</b>	<b>\$ 3,791,430</b>

**f) Legal Proceedings**

There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

**Note 10 – Subsequent Events**

None.

**END NOTES TO FINANCIALS**

---

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

### *Cautionary Note Regarding Forward-Looking Statements*

*This Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018, or this Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. These statements include, among other things, any predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy; statements concerning clinical studies and results, statements concerning industry trends; statements regarding anticipated demand for our products, or the products of our competitors, statements relating to manufacturing forecasts, and the potential impact of our relationship with contract manufacturers and original equipment manufacturers on our business; statements relating to the commercialization of our products, assumptions regarding the future cost and potential benefits of our research and development efforts; forecasts of our liquidity position or available cash resources; statements relating to the impact of pending litigation; and statements relating to the assumptions underlying any of the foregoing. Throughout this Report, we have attempted to identify forward-looking statements by using words such as “may,” “believe,” “will,” “could,” “project,” “anticipate,” “expect,” “estimate,” “should,” “continue,” “potential,” “plan,” “forecasts,” “goal,” “seek,” “intend,” other forms of these words or similar words or expressions or the negative thereof (although not all forward-looking statements contain these words).*

*We have based our forward-looking statements on our current expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this Report. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include our failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical in-vitro diagnostics, or IVD market; a failure by the marketplace to accept the products in our development pipeline or any other diagnostic products we might develop; we will face fierce competition and our intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified elsewhere in this Report, as well as in our other filings with the Securities and Exchange Commission, or the SEC. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, readers are cautioned not to place undue reliance on any forward-looking statements.*

*You should read this Report in its entirety, together with our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the SEC on March 1, 2018, or our Annual Report, the documents that we file as exhibits to this Report and the documents that we incorporate by reference into this Report, with the understanding*



*that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations. If we do update or correct any forward-looking statements, readers should not conclude that we will make additional updates or corrections.*

---

## *Company Overview*

VolitionRx is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers. We hope that through earlier diagnosis we can help save and improve the quality of many people's lives throughout the world.

Our tests are based mainly on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. We have developed a novel suite of blood assays for epigenetically altered circulating nucleosomes as biomarkers in cancer. Nu.Q products are simple, low-cost, ELISA platform tests and can incorporate other off patent, low cost ELISA tests in our panels (e.g. CEA, PSA, and CA125) for higher accuracy.

Our diagnostic target in the blood includes the same tumor chromosome fragment as targeted by ctDNA tests, but our approach is to test for chromosome protein and nucleic acid changes in intact chromosome fragments by ELISA, rather than chemically extracting, amplifying, and sequencing the ctDNA and discarding the rest of the nucleosome. ELISA is possible because the targets of our tests occur globally across all nucleosomes within a tumor cell, whereas individual ctDNA changes must be identified within the three billion base-pair genomes. This means that the targets of our tests are exponentially more prevalent in circulating blood, and detectable using simple laboratory methods.

We are developing blood-based diagnostics for the most prevalent cancers, beginning with colorectal cancer, or CRC. Following CRC, we anticipate focusing on lung cancer, prostate and pancreatic cancer, using our Nucleosomics biomarker discovery platform. Our development pipeline includes assays to be used for symptomatic patients or asymptomatic (screening) populations. The platform employs a range of simple Nu.Q immunoassays on an industry standard ELISA format, which allows rapid quantification of epigenetic changes in biofluids (whole blood, plasma, serum, sputum, urine, etc.) compared to other more complicated and expensive approaches such as bisulfite conversion and polymerase chain reaction. Our Nu.Q biomarkers can be used alone, or in combination to generate profiles related to specific conditions.

We have developed thirty-nine Nu.Q™ blood-based assays to date to detect specific biomarkers that can be used individually or in combination to generate a profile which forms the basis of a product for a particular cancer or disease. We are also looking at a range of additional low cost orthogonal ELISA markers that may add to the test accuracy while maintaining our aim of providing a low-cost test that requires only a small amount of blood.

We anticipate that because of their ease of use and cost efficiency, our tests have the potential to become the first method of choice for cancer diagnostics, allowing detection of a range of cancers at an earlier stage. We anticipate the initial use will be for the testing of individuals who, for reasons such as time, cost, or aversion to current methods, are not currently screened, or are not up to date with their screening.

We intend to commercialize our products in the future through various channels within the European Union, the United States and throughout the rest of the world, beginning with Asia. Patient compliance is critical for asymptomatic CRC population screening programs; however, current CRC screening programs have poor compliance. For example, in the United States there are several recommended CRC screening test options, including: colonoscopy, fecal tests and computed tomography colonoscopy; however, the participation rate as of 2014 was just 65.7% of the eligible patient population. The UK, like many European countries, employs a front-line fecal test for screening that also has a low compliance rate of between 59% and 67%. These figures indicate that about one-third of the populations of the United States and the UK are unscreened. The unscreened populations of many other countries are much higher. This low level of screening participation is a serious issue as it often leads to the late diagnosis of cancer when it is much harder to treat.

We believe that the only viable option to achieve high levels of compliance will come from affordable blood tests that use a small amount of blood taken as part of the patient's normal health check procedure. We aim to launch such a front-line CRC population screening test for asymptomatic people who are non-compliant with current screening methods in Europe in 2018 and in Asia soon after. This product will require a small amount of blood and will use the same established, robust, low-cost ELISA methodology employed in the PSA test for prostate cancer.

### ***Overview of Plan of Operations***

We have identified the specific processes and resources required to achieve the near and medium-term objectives of our business plan, including personnel, facilities, equipment, research and testing materials including antibodies and clinical samples, and the protection of intellectual property. To date, operations have proceeded satisfactorily in relation to our business plan. However, it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost. It is also possible that the results of some processes may not be as expected and that modifications of procedures and materials may be required. Such events could result in delays to the achievement of the near and medium-term objectives of our business plan, in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD market.

Our future as an operating business will depend on our ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain our operations. Management plans to address the above as needed by: (a) securing additional grant funds; (b) obtaining additional equity or debt financing; (c) granting licenses to third parties in exchange for specified up-front and/or back end payments; and (d) developing and commercializing our products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.

Our ability to continue as a going concern is dependent upon our accomplishment of the plans described in the preceding paragraph and eventually to attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. If we are unable to obtain adequate capital, we could be forced to cease operations.

### ***Liquidity and Capital Resources***

We have financed our operations since inception primarily through private placements and public offerings of our common stock. As of March 31, 2018, we had cash and cash equivalents of approximately \$14.3 million.

Net cash used in operating activities was \$3.5 million and \$2.7 million for the three-months ended March 31, 2018 and March 31, 2017, respectively. The increase in cash used in operating activities for the period ended March 31, 2018 when compared to same period in 2017 was primarily due to increased expenditures on research and development activities, as well as increased general and administrative activities, including increases to stock-based compensation.

Net cash used in investing activities was \$0.1 million and \$0.9 million for the three-months ended March 31, 2018 and March 31, 2017, respectively. The decrease in cash used in investing activities for the period ended March 31, 2018 when compared to same period in 2017 was primarily a result of the purchase of equipment and facility improvements for the new research and development facility in Belgium and investment in our information technology infrastructure

in 2017.

Net cash provided by financing activities was \$7.7 million and \$0.3 million for the three-months ended March 31, 2018 and March 31, 2017, respectively. The increase in cash provided by financing activities for the period ended March 31, 2018 when compared to same period in 2017 was primarily the result of \$7.8 million in net cash proceeds raised in March 2018 through the sale and issuance of 3.5 million shares of common stock in a public offering.

We intend to use our cash reserves to predominantly fund further research and development activities. We do not currently have any substantial source of revenues and expect to rely on additional future financing, through the sale of equity or debt securities, or the sale of licensing rights. There is no assurance that we will be successful in raising further funds.

In the event that additional financing is delayed, we will prioritize the maintenance of our research and development personnel and facilities, primarily in Belgium, and the maintenance of our patent rights. The completion of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD market would be delayed. In the event of an ongoing lack of financing, it may be necessary to discontinue operations, which will adversely affect the value of our common stock.

We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors stated in their report on our audited financial statements for the fiscal year ended December 31, 2017 that they have substantial doubt that we will be able to continue as a going concern without further financing.

The following table summarizes our approximate contractual payments due by year as of March 31, 2018.

**Approximate Payments (Including Interest) Due by Year**

Description	Total \$	2018 (Remaining) \$	2019 - 2022 \$	2023 + \$
Capital Lease Obligations	1,163,215	125,862	415,801	621,552
Operating Lease Obligations	297,863	164,704	133,159	-
Grants Repayable	237,173	43,143	163,212	30,818
Long-Term Debt <sup>(1)</sup>	3,012,884	461,570	1,757,362	793,952
Collaborative Agreement Obligations	3,791,430	2,228,334	1,563,096	-
Total	8,502,565	3,023,613	4,032,630	1,446,322

<sup>(1)</sup> Long-term debt includes the total value of the SOFINEX loan of €1.0 million Euros, although only €250,000 Euros had been drawn down as of March 31, 2018. See Note 9(d) to the Consolidated Financial Statements for further details.

**Results of Operations**

**Comparison of the Three-Months Ended March 31, 2018 and March 31, 2017.**

The following table sets forth our results of operations for the three-months ended on March 31, 2018 and March 31, 2017, respectively.

	Three-Months Ended March 31,		Increase	Percentage Increase
	2018	2017	(Decrease)	(Decrease)
	\$	\$	\$	%
Revenues	-	-	-	-
Research and development	(2,423,202)	(1,668,386)	754,816	45%
General and administrative	(1,842,093)	(1,400,684)	441,409	32%
Sales and marketing	(364,144)	(269,408)	94,736	35%

Total Operating Expenses	(4,629,439)	(3,338,478)	1,290,961	39%
Interest expense	(22,982)	(12,205)	10,777	88%
Net Loss	(4,652,421)	(3,350,683)	1,301,738	39%
Loss Per Share – Basic and Diluted	(0.17)	(0.13)	0.04	31%
Weighted Average Shares Outstanding - Basic and Diluted	27,265,249	26,128,934	1,136,315	4%

### Revenues

Our operations are still predominantly in the research and development stage and we had no revenues during the three-months ended March 31, 2018 and March 31, 2017, respectively.

### Operating Expenses

Total operating expenses increased to \$4.6 million for the three-months ended March 31, 2018 from \$3.3 million for the three-months ended March 31, 2017.

**Research and Development Expenses**

Research and development expenses increased to \$2.4 million for the three-months ended March 31, 2018 from \$1.7 million for the three-months ended March 31, 2017. This increase in overall research and development expenditures was primarily related to our participation in the trial with the University of Michigan and increased headcount during the period.

	<b>Three-Months Ended March 31,</b>		
	<b>2018</b>	<b>2017</b>	<b>Change</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Personnel expenses	962,340	518,718	443,622
Stock-based compensation	214,507	192,371	22,136
Direct research and development expenses	920,732	581,076	339,656
Other research and development	173,341	282,586	(109,245)
Depreciation and amortization	152,282	93,635	58,647
Total Research and Development expenses	2,423,202	1,668,386	754,816

**General and Administrative Expenses**

General and administrative expenses increased to \$1.8 million for the three-months ended March 31, 2018, from \$1.4 million for the three-months ended March 31, 2017. This increase in overall general and administrative expenditures was primarily due to higher legal and professional fees and increased stock-based compensation during the period.

	<b>Three-Months Ended March 31,</b>		
	<b>2018</b>	<b>2017</b>	<b>Change</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Personnel expenses	545,084	522,138	22,946
Stock-based compensation	619,495	401,455	218,040
Legal and professional fees	576,253	274,252	302,001
Other general and administrative	92,156	202,839	(110,683)
Depreciation and amortization	9,105	-	9,105
Total General and Administrative expenses	1,842,093	1,400,684	441,409



**Sales and Marketing Expenses**

Sales and marketing expenses increased to \$0.4 million for the three-months ended March 31, 2018, from the \$0.3 million for the three-months ended March 31, 2017. This increase in overall sales and marketing expenditures was primarily related to increased marketing professional fees and stock-based compensation offset by less expenditure on travel expenses during the period.

	<b>Three-Months Ended March 31,</b>		
	<b>2018</b>	<b>2017</b>	<b>Change</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Personnel expenses	154,917	232,124	(77,207)
Stock-based compensation	63,423	379	63,044
Direct marketing and professional fees	145,804	36,905	108,899
Total Sales and Marketing expenses	364,144	269,408	94,736

***Other Expenses***

For the three-months ended March 31, 2018, the Company's other expenses were \$22,982 compared to \$12,205 for the three-months ended March 31, 2017.

***Net Loss***

For the three-months ended March 31, 2018, the Company's net loss was \$4.7 million, an increase of approximately \$1.3 million, or 39%, in comparison to a net loss of \$3.4 million for the three-months ended March 31, 2017. The change was a result of the factors described above.

### ***Off-Balance Sheet Arrangements***

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

### ***Future Financings***

We may seek to obtain additional capital through the sale of debt or equity securities, if we deem it desirable or necessary. However, we may be unable to obtain such additional capital when needed, or on terms favorable to us or our stockholders, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If additional funds are raised through the issuance of debt securities, the terms of such securities may place restrictions on our ability to operate our business.

### ***Critical Accounting Policies***

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, applied on a consistent basis. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

### ***Recently Issued Accounting Pronouncements***

The Company has implemented all applicable new accounting pronouncements that are in effect. The Company does not believe that there are any other applicable new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information under this item.

### **ITEM 4. CONTROLS AND PROCEDURES**

#### *Evaluation of Disclosure Controls and Procedures*

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our Principal Executive and Principal Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded, as they previously concluded as of December 31, 2017, that our disclosure controls and procedures continue to not be effective as of March 31, 2018, because of material weaknesses in our internal control over financial reporting, as described below and in detail in our Annual Report.

***Changes in Internal Control over Financial Reporting***

The Audit Committee of the Board of Directors meets regularly with our financial management, and with the independent registered public accounting firm engaged by us. Internal accounting controls and the quality of financial reporting are discussed during these meetings. The Audit Committee has discussed with the independent registered public accounting firm matters required to be discussed by the auditing standards adopted or established by the Public Company Accounting Oversight Board (“PCAOB”). In addition, the Audit Committee and the independent registered public accounting firm have discussed the independent registered public accounting firm’s independence from the Company and its management, including the matters in the written disclosures required by PCAOB Rule 3526 “Communicating with Audit Committees Concerning Independence.”

As of March 31, 2018, we did not maintain sufficient internal controls over financial reporting:

due to a lack of adequate segregation of duties in some areas of Finance; and

due to a lack of sufficient oversight in the area of IT, where certain processes may affect the internal controls over financial reporting.

We have developed, and are currently implementing, a remediation plan for such weaknesses. Specifically, we have identified and selected a system for financial reporting that will allow further automation of the reporting process, thereby strengthening the control environment over financial reporting.

As we continue to evaluate and work to enhance our internal controls over financial reporting, we may determine that additional measures should be taken to address these or other control deficiencies, and/or that we should modify our remediation plan.

There have been no changes in our internal controls over financial reporting that occurred during the fiscal quarter ended March 31, 2018, other than those described above, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

***Limitations of the Effectiveness of Disclosure Controls and Internal Controls***

Our management, including our Principal Executive Officer and Principal Financial Officer, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## **PART II - OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

In the ordinary course of business, we may be subject to claims, counter claims, suits and other litigation of the type that generally arise from the conduct of our business. We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our directors, officers or any affiliates, or any registered or beneficial shareholders, is an adverse party or has a material interest adverse to our interest.

### **ITEM 1A. RISK FACTORS**

There have been no material changes in our assessment of risk factors affecting our business since those presented in Part I, Item 1A of our Annual Report.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not Applicable.

**ITEM 5. OTHER INFORMATION**

None.

**ITEM 6. EXHIBITS**

Exhibit Number	Exhibit Description	Incorporated by Reference			Filing Date	Filed Herewith
		Form	File No.	Exhibit		
<u>10.1</u>	Underwriting Agreement, dated March 9, 2018, by and between the Company and Oppenheimer & Co., Inc., as representative of the several Underwriters named therein.	8-K	001-36833	1.1	March 12, 2018	
<u>31.1</u>	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.					X
<u>31.2</u>						X

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

<u>32.1*</u>	Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	X
101.INS	XBRL Instance Document.	X
101.SCH	XBRL Taxonomy Extension Schema Document.	X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.	X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.	X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.	X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.	X

\*The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**VOLITIONRX LIMITED**

Dated May 10, 2018

By: */s/ Cameron Reynolds*

Cameron Reynolds

President and Chief Executive Officer

(Authorized Signatory and Principal Executive Officer)

Dated May 10, 2018

By: */s/ David Vanston*

David Vanston

Chief Financial Officer and Treasurer

(Authorized Signatory and Principal Financial and Accounting Officer)